Related Experiment Video
Updated: Jan 21, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4,
Oleg Milberg1, Chang Gong2, Mohammad Jafarnejad2
1Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. oleg.milberg@gmail.com.
Abstract:
Over the past decade, several immunotherapies have been approved for the treatment of melanoma. The most prominent of these are the immune checkpoint inhibitors, which are antibodies that block the inhibitory effects on the immune system by checkpoint receptors, such as CTLA-4, PD-1 and PD-L1. Preclinically, blocking these receptors has led to increased activation and proliferation of effector cells following stimulation and antigen recognition, and subsequently, more effective elimination of cancer cells. Translation from preclinical to clinical outcomes in solid tumors has shown the existence of a wide diversity of individual patient responses, linked to several patient-specific parameters. We developed a quantitative systems pharmacology (QSP) model that looks at the mentioned checkpoint blockade therapies administered as mono-, combo- and sequential therapies, to show how different combinations of specific patient parameters defined within physiological ranges distinguish different types of virtual patient responders to these therapies for melanoma. Further validation by fitting and subsequent simulations of virtual clinical trials mimicking actual patient trials demonstrated that the model can capture a wide variety of tumor dynamics that are observed in the clinic and can predict median clinical responses. Our aim here is to present a QSP model for combination immunotherapy specific to melanoma.
Insights
This study presents a quantitative systems pharmacology (QSP) model for melanoma immunotherapy. The model simulates patient responses to immune checkpoint inhibitors, predicting clinical outcomes for various treatment combinations.
Area of Science:
- Immunology
- Pharmacology
- Computational Biology
Background:
- Immunotherapies, particularly immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, and PD-L1, have revolutionized melanoma treatment.
- Preclinical studies show ICIs enhance anti-tumor immune responses, but clinical outcomes vary significantly among patients.
- Patient-specific factors contribute to the diverse responses observed in solid tumors treated with ICIs.
Purpose of the Study:
- To develop a quantitative systems pharmacology (QSP) model for simulating melanoma responses to immune checkpoint blockade therapies.
- To investigate how combinations of patient-specific parameters influence virtual patient responses to mono-, combo-, and sequential ICI therapies.
- To provide a predictive model for understanding and optimizing combination immunotherapy strategies in melanoma.
Main Methods:
- Development of a QSP model incorporating key parameters of immune checkpoint blockade.
- Simulation of various therapeutic regimens: monotherapy, combination therapy, and sequential therapy.
- Validation of the QSP model by fitting to actual clinical trial data and simulating virtual clinical trials.
- Analysis of how distinct patient parameter combinations differentiate virtual patient responders.
Main Results:
- The QSP model successfully captures the diverse tumor dynamics observed in clinical settings.
- Simulations demonstrate the model's ability to predict median clinical responses across different patient profiles.
- The model identifies specific combinations of patient parameters associated with varying responses to immunotherapy.
Conclusions:
- The developed QSP model serves as a valuable tool for understanding patient-specific responses to melanoma immunotherapy.
- This model can aid in predicting treatment efficacy and optimizing combination immunotherapy strategies.
- Further application of this QSP model holds promise for personalized medicine approaches in melanoma treatment.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Related Concept Videos
01:26PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
01:07Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
01:24Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...
02:27Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
01:29Neuromuscular Junction And Blockade
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...